Vivet raises €37.5m to advance gene therapies for metabolic diseases
Vivet Therapeutics, which is focused on developing novel gene therapies for rare, inherited metabolic diseases, has raised €37.5m in a Series A financing round.
Vivet Therapeutics, which is focused on developing novel gene therapies for rare, inherited metabolic diseases, has raised €37.5m in a Series A financing round.
Poxel has announced positive top line results of a Phase 2b trial of Imeglimin for type 2 diabetes treatment in Japan.
Sosei has agreed to make an investment in and acquire an exclusive option to potentially acquire MiNA Therapeutics, a private UK biopharmaceutical company.
AstraZeneca will develop new inhaled respiratory treatments based on Pieris Pharmaceuticals’ Anticalin platform through a collaboration that could generate more than $2bn for the US firm.
Shire has secured exclusive global rights to develop Parion Sciences' Phase II-stage epithelial sodium channel (ENaC) inhibitor P-321 for the potential treatment of dry eye.
Takeda Pharmaceutical has entered into a multi-year partnership with Harrington Discovery Institute at University Hospitals in Cleveland, Ohio to advance the development of rare disease rherapeutics.
Clinical-stage biopharmaceutical firm Arsanis has secured $45.5m in a Series D financing round led by the Bill & Melinda Gates Foundation.
Immune Pharmaceuticals has entered into a letter of intent with Pint Pharma regarding license and commercializion of Ceplene in Latin America.
Alpine Immune Sciences has agreed to merge with a subsidiary of Nivalis Therapeutics in an all-stock transaction.
Lyndra has secured $23m Series A financing, led by Polaris Partners, with participation from Quark Venture and GF Securities, Yonghua Capital, Healthlink Capital, Suffolk Equity, Partners Healthcare among others.